Health Catalyst stock falls 2.24 percent as CEO reset unfolds
Published on 09/29/2026 at 20:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Health Catalyst (ISIN US42226A1079) stock was trading at EUR 76.50 at Lang & Schwarz on September 29, 2026 at 8:48 p.m. CEST, down 2.24 percent from the prior close of EUR 78.25. The move came as the healthcare intelligence company works through a leadership transition and a smaller post-divestiture business.
CEO transition sets a new course
According to Health Catalyst on September 8, 2026, Simeon Kohl became chief executive officer and president effective September 14, 2026. Ben Albert moved to chief business officer and left the board on September 13, 2026, giving the company a new operating leadership structure.
The change follows a strategic reset centered on healthcare data, analytics and artificial intelligence. Health Catalyst describes its platform as a combination of cloud data technology, analytics software and professional services for healthcare organizations.
Q2 revenue beat the guidance range
ScanX reported Q2 2026 revenue of USD 70.50 million, USD 0.50 million above the high end of the USD 68.00 million to USD 70.00 million guidance range. Adjusted EBITDA reached USD 9.90 million, matching the top of its USD 9.00 million to USD 10.00 million target, while adjusted gross margin expanded to 51.00 percent from 50.00 percent in Q2 2025.
The same report put technology revenue at USD 48.80 million and professional services revenue at USD 21.70 million for Q2 2026. Health Catalyst guided to full-year 2026 revenue of USD 246.00 million to USD 249.00 million and adjusted EBITDA of USD 18.00 million to USD 18.50 million.
Debt reduction changes the risk profile
ScanX reported that Health Catalyst sold Vitalware for USD 147.00 million and used the proceeds with cash on hand to repay USD 160.00 million of credit facility debt. That transaction improves the balance sheet, but the exit also removes a revenue stream and leaves migration execution as a central operating issue.
For the next quarter, management expects revenue of USD 55.00 million to USD 56.00 million and adjusted EBITDA between breakeven and USD 0.50 million. The forecast places greater weight on platform migrations and cost discipline than on near-term top-line expansion.
Analysts keep a Hold consensus
MarketBeat reported a Hold consensus from 11 analysts, with seven Hold ratings, three Buy ratings and one Sell rating. The average 12-month price target was USD 2.45, while Wells Fargo had cut its target to USD 1.50 and Canaccord Genuity had reduced its target to USD 1.80.
Health Catalyst stock trades lower
Health Catalyst stock was trading at EUR 76.50 at Lang & Schwarz on September 29, 2026 at 8:48 p.m. CEST, down 2.24 percent versus the Lang & Schwarz prior close of EUR 78.25. The primary Nasdaq listing showed a 52-week range of USD 0.95 to USD 3.62 and market capitalization of USD 127.5 million as of September 29, 2026.
Health Catalyst stock key data
- Company: Health Catalyst, Inc.
- ISIN: US42226A1079
- Ticker: HCAT
- Primary exchange: Nasdaq Global Select Market
- Price Lang & Schwarz (as of September 29, 2026, 8:48 p.m. CEST): EUR 76.50
- Change versus prior close: minus 2.24 percent
- Prior close Lang & Schwarz (September 28, 2026): EUR 78.25
- Market capitalization: USD 127.5 million (as of September 29, 2026)
- 52-week range: USD 0.95-3.62 (as of September 29, 2026)
- Sector / Industry: Healthcare / Medical Healthcare Information Services
